Howard I Rutman, Age 68401 80Th St, New York, NY 10001

Howard Rutman Phones & Addresses

401 80Th St, New York, NY 10001

401 E 80Th St APT 33D, New York, NY 10075

Baltimore, MD

Work

Company: Division of Cardiology-Montefiore-Einstein Address: 111 E 210Th St, Bronx, NY 10467 Phones: (718) 920-5528 (Phone)

Education

School / High School: Johns Hopkins University School Of Medicine 1981

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Cardiovascular Disease, 1987

Mentions for Howard I Rutman

Career records & work history

Medicine Doctors

Howard Rutman Photo 1

Dr. Howard I Rutman, Bronx NY - MD (Doctor of Medicine)

Specialties:
Cardiology
Address:
Division of Cardiology-Montefiore-Einstein
111 E 210Th St, Bronx, NY 10467
(718) 920-5528 (Phone)
65 E 96Th St, New York, NY 10128
(212) 426-7300 (Phone)
Conditions:
Arrhythmias (incl. Atrial Fibrillation)
Hypertension
Mitral Valve Disease
Certifications:
Cardiovascular Disease, 1987
Internal Medicine, 1984
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Division of Cardiology-Montefiore-Einstein
111 E 210Th St, Bronx, NY 10467
65 E 96Th St, New York, NY 10128
Montefiore Medical Center
111 East 210Th Street, Bronx, NY 10467
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1981
Medical School
Ny Hosp/Cornell Med Center
Graduated: 1984
Medical School
Einstein
Graduated: 1986

Howard I. Rutman

Specialties:
Cardiovascular Disease
Work:
Montefiore Medical Center Cardiology
111 E 210 St, Bronx, NY 10467
(718) 920-5882 (phone) (718) 920-7447 (fax)
Education:
Medical School
Johns Hopkins University School of Medicine
Graduated: 1981
Procedures:
Echocardiogram, Electrocardiogram (EKG or ECG)
Languages:
English, Spanish
Description:
Dr. Rutman graduated from the Johns Hopkins University School of Medicine in 1981. He works in Bronx, NY and specializes in Cardiovascular Disease. Dr. Rutman is affiliated with Bronx Lebanon Hospital Center and Montefiore Medical Center.

Howard Rutman resumes & CV records

Resumes

Howard Rutman Photo 18

Group Vice President, Medical Director At Taro Pharmaceuticals

Location:
United States
Industry:
Pharmaceuticals
Howard Rutman Photo 19

Vice President Medical Affairs

Location:
New York, NY
Industry:
Pharmaceuticals
Work:
Taro Pharmaceuticals since Apr 2003
Group Vice President, Medical Director
Mount Sinai School of Medicine since Jul 1988
Attending
Albert Einstein College of Medicine since Jun 1986
Cardiology Attending
Montefiore Hospital Jul 1986 - Apr 2007
Attending
Education:
New York University - Leonard N. Stern School of Business 2000 - 2002
MBA, Management
The Johns Hopkins University School of Medicine 1977 - 1981
MD
Harvard University 1973 - 1977
AB, Biochemical Sciences
Skills:
Clinical Development, Clinical Research, Drug Development, Cardiology, Pharmaceutical Industry, Medical Affairs, Clinical Trials, Pharmacovigilance, Oncology, Biotechnology, Dermatology, Medicine, Pharmaceutics, Commercialization, Lifesciences, Life Sciences, Regulatory Affairs, Fda, Neurology, Medical Devices, Infectious Diseases, Gcp, Managed Care, Internal Medicine, Drug Discovery, Pediatrics, Medical Education, Immunology, Good Clinical Practice, Translational Research, Hematology, Epidemiology, Cancer, Sop, Neuroscience, Standard Operating Procedure, U.s. Food and Drug Administration
Howard Rutman Photo 20

Howard Rutman

Publications & IP owners

Us Patents

Topical Gel Formulation Comprising Organophosphate Insecticide And Preparation Thereof

US Patent:
8012498, Sep 6, 2011
Filed:
Jul 12, 2005
Appl. No.:
11/179719
Inventors:
Sandhya Goyal - Ryebrook NY, US
Subhas Kundu - Tappan NY, US
Daniel Moros - Larchmont NY, US
Howard Rutman - New York NY, US
Avraham Yacobi - Englewood NY, US
International Classification:
A01N 57/10
A01N 57/12
A61K 9/06
A61K 31/661
A61K 47/38
A61P 33/14
US Classification:
424405, 424407, 514122, 514781
Abstract:
The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0. 1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

Composition And Method For Improved Bioavailability And Enhanced Brain Delivery Of 5,5-Diphenyl Barbituric Acid

US Patent:
8076346, Dec 13, 2011
Filed:
Jan 19, 2010
Appl. No.:
12/689757
Inventors:
Daniella Gutman - Rishon Lezion, IL
Barrie Levitt - Mamaroneck NY, US
Daniel A. Moros - Larchmont NY, US
Avraham Yacobi - Englewood NJ, US
Howard Rutman - New York NY, US
Assignee:
Taro Pharamaceutical Industries Ltd. - Haifa Bay
International Classification:
A61K 31/515
C07D 239/64
US Classification:
514270, 544305
Abstract:
The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

Topical Gel Formulation Comprising Organophosphate Insecticide And Preparation Thereof

US Patent:
8158139, Apr 17, 2012
Filed:
Feb 9, 2006
Appl. No.:
11/351188
Inventors:
Sandhya Goyal - Ryebrook NY, US
Subhas Kundu - Tappan NY, US
Daniel Moros - Latchmont NY, US
Howard Rutman - New York NY, US
Avraham Yacobi - Englewood NJ, US
Assignee:
Taro Pharmaceuticals North America, Inc. - Grand Cayman
International Classification:
A01N 57/10
A01N 57/12
A01N 25/02
A61K 9/08
A61K 31/661
A61K 47/10
A61K 47/14
A61P 33/14
US Classification:
424405, 514122, 514786
Abstract:
The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0. 1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present topical formulations encompass a non-flammable solvent for malathion effective in killing head lice. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

Topical Gel Formulation Comprising Insecticide And Its Preparation Thereof

US Patent:
2006012, Jun 8, 2006
Filed:
Jul 12, 2005
Appl. No.:
11/179924
Inventors:
Sandhya Goyal - Ryebrook NY, US
Subhas Kundus - Tappan NY, US
Daniel Moros - Larchmont NY, US
Howard Rutman - New York NY, US
Avraham Yacobi - Englewood NJ, US
International Classification:
A01N 65/00
A01N 25/00
A01N 43/04
A01N 55/00
A01N 43/30
A01N 29/04
US Classification:
424405000, 514028000, 514065000, 514063000, 514464000, 514747000
Abstract:
The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

Composition And Method For Improved Bioavailability And Enhanced Brain Delivery Of 5,5-Diphenyl Barbituric Acid

US Patent:
2006012, Jun 8, 2006
Filed:
Aug 10, 2005
Appl. No.:
11/201024
Inventors:
Daniella Gutman - Rishon Lezion, IL
Daniel Moros - Larchmont NY, US
Avraham Yacobi - Englewood NJ, US
Howard Rutman - New York NY, US
International Classification:
A61K 31/515
US Classification:
514270000
Abstract:
The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

Topical Gel Formulation Comprising Organophosphate Insecticide And Preparation Thereof

US Patent:
2012005, Mar 1, 2012
Filed:
Aug 30, 2011
Appl. No.:
13/220935
Inventors:
Sandhya Goyal - Ryebrook NY, US
Subhas Kundu - Tappan NY, US
Daniel Moros - Larchmont NY, US
Howard Rutman - New York NY, US
Avraham Yacobi - Englewood NJ, US
Assignee:
Taro Pharmaceuticals North America, Inc. - Grand Cayman
International Classification:
A61K 31/6615
A61P 33/14
US Classification:
514122
Abstract:
The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a ketone, a glycol and a mixture thereof, wherein the organic solvent contains at least about 40% by weight of the lower alkyl alcohol; and c) at least one polymer selected from the group consisting of a cellulosic polymer, acrylates, methacrylates, and polyvinyl pyrrolidone. The present gel pharmaceutical formulation preferably contains malathion and optionally contains isopropyl myristate. The present invention further provides a process of preparing as well as a method of treating ectoparasites in a mammal using the same.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.